Industry: Pharmaceuticals (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-07-10 | New | $361,500 | $361,500 | Equity Only | 06b | SEC link |
| 2023-08-25 | New | $250,000 | $250,000 | Equity Only | 06b | SEC link |
| 2023-03-15 | New | $2,100,000 | $2,100,000 | Equity Only | 06b | SEC link |
| 2021-09-29 | New | $1,000,000 | $1,000,000 | Equity Only | 06b | SEC link |
| 2021-01-11 | New | $45,000 | $45,000 | Equity Only | 06b | SEC link |
| 2021-01-11 | Amended | $45,000 | $0 | Equity Only | 06b | SEC link |
| 2020-03-20 | Amended | $350,000 | $0 | Equity Only | 06b | SEC link |
| 2020-03-19 | New | $425,000 | $350,000 | Equity Only | 06b | SEC link |
| 2019-10-21 | Amended | $175,045 | $175,045 | Equity Only | 06b | SEC link |
| 2019-09-05 | New | Yet to Sell | $0 | Equity Only | 06b | SEC link |
| 2019-07-09 | New | $125,000 | $125,000 | Equity Only | 06b | SEC link |
| 2019-06-06 | New | $200,000 | $200,000 | Equity Only | 06b | SEC link |
| 2017-05-22 | New | $1,199,000 | $1,199,000 | Equity Only | 06b | SEC link |
| Name | Role |
|---|---|
| Jonathan Balfour | Executive |
| Richard Deslauriers | Director |
| Bill Doyle | Director, Executive |
| William F. Doyle | Director |
| Robert F. Jacobs | Executive |
| Richard Rosene | Director, Executive |
| Brad Rummer | Director |
| Kyle Salem | Executive |